Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women

European Journal of Clinical Pharmacology

Volumn 67, Issue 10, 2011, Pages 1017-1025

  Tanii, Hiromi ^a,b   Shitara, Yoshihisa ^b   Horie, Toshiharu ^b  

^a NOVARTIS PHARMA K K   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

CYP2A6; Letrozole; NONMEM; Pharmacogenomics; Population pharmacokinetic analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; LETROZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOCHROME P450 2A6 GENE; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; JAPANESE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; REGULATOR GENE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; BODY WEIGHT; CREATININE; ESTRADIOL; ESTRONE; FEMALE; GENOTYPE; HUMANS; NITRILES; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TRIAZOLES;

EID: 80054726011     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1042-3     Document Type: Article

References (23)

1. JD Yager NE Davidson 2006 Estrogen carcinogenesis in breast cancer N Engl J Med 354 270 282 16421368 10.1056/NEJMra050776 1:CAS:528: DC%2BD28Xls1KjtQ%3D%3D (Pubitemid 43113032)
2. SR Johnston M Dowsett 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory Nat Rev Cancer 3 821 831 14668813 10.1038/nrc1211 1:CAS:528:DC%2BD3sXptFKmur8%3D (Pubitemid 37376980)
3. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 9828250 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D (Pubitemid 28536137)
4. FP Guengerich 2003 Cytochromes P450, drugs, and diseases Mol Interv 3 194 204 14993447 10.1124/mi.3.4.194 1:CAS:528:DC%2BD3sXmtFWitLs%3D
5. S Amar V Roy EA Perez 2007 Letrozole: present and future role in the treatment of breast cancer Expert Opin Pharmacother 8 1965 1975 17696797 10.1517/14656566.8.12.1965 1:CAS:528:DC%2BD2sXhtVGjs73E (Pubitemid 47321526)
6. A Brodie 2002 Aromatase inhibitors in breast cancer Trends Endocrinol Metab 13 61 65 11854020 10.1016/S1043-2760(01)00529-X 1:CAS:528: DC%2BD38Xht1ajurg%3D (Pubitemid 36740448)
7. A Sioufi N Gauducheau V Pineau F Marfil A Jaouen JM Cardot J Godbillon C Czendlik H Howald C Pfister F Vreeland 1997 Absolute bioavailability of letrozole in healthy postmenopausal women Biopharm Drug Dispos 18 779 789 9429742 10.1002/(SICI)1099-081X(199712)18:9<779::AID-BDD64>3.0.CO;2-5 1:CAS:528:DyaK1cXmslSi (Pubitemid 27517567)
8. CU Pfister A Martoni C Zamagni G Lelli F De Braud C Souppart M Duval U Hornberger 2001 Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients Biopharm Drug Dispos 22 191 197 11745921 10.1002/bdd.273 1:CAS:528:DC%2BD3MXptlKqur4%3D (Pubitemid 33133815)
9. K Murai H Yamazaki K Nakagawa R Kawai T Kamataki 2009 Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes Xenobiotica 39 795 802 19845430 10.3109/00498250903171395 1:CAS:528:DC%2BD1MXht12hu77O
10. M Nakajima Y Kuroiwa T Yokoi 2002 Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6 Drug Metab Rev 34 865 877 12487152 10.1081/DMR-120015696 1:CAS:528:DC%2BD38Xpslegurc%3D
11. S Daigo Y Takahashi M Fujieda N Ariyoshi H Yamazaki W Koizumi S Tanabe K Saigenji S Nagayama K Ikeda Y Nishioka T Kamataki 2002 A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur Pharmacogenetics 12 299 306 12042667 10.1097/00008571-200206000-00005 1:CAS:528:DC%2BD38XnsFKru7k%3D (Pubitemid 34620657)
12. C Xu YS Rao B Xu E Hoffmann J Jones EM Sellers RF Tyndale 2002 An in vivo pilot study characterizing the new CYP2A6*7,*8, and*10 alleles Biochem Biophys Res Commun 290 318 324 11779172 10.1006/bbrc.2001.6209 1:CAS:528:DC%2BD38XhsFCmtA%3D%3D (Pubitemid 34694502)
13. F Marfil V Pineau A Sioufi SJ Godbillon 1996 High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection J Chromatogr B Biomed Appl 683 251 258 8891923 10.1016/0378-4347(96) 00118-1 1:CAS:528:DyaK28XmtFekurg%3D (Pubitemid 26319570)
14. A Lipton LM Demers HA Harvey KB Kambic H Grossberg C Brady H Adlercruetz PF Trunet RJ Santen 1995 Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer Cancer 15 2132 2138 10.1002/1097-0142(19950415)75:8<2132::AID-CNCR2820750816>3.0.CO;2-U
15. M Nevilie R Selzer B Aizenstein M Maguire K Hogan R Walton K Welsh B Neri M de Arruda 2002 Characterization of cytochrome P450 2D6 alleles using the Invader system Biotechniques 32 Suppl 34 43
16. Wirz B, Valles B, Parkinson A, Madan A, Probst A, Zimmerlin A, Gut J (1996) CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. Proceedings of 7th North American ISSX Meeting 10:359
17. V Pichette FA Leblond 2003 Drug metabolism in chronic renal failure Curr Drug Metab 4 91 103 12678690 10.2174/1389200033489532 1:CAS:528: DC%2BD3sXjtVWmu74%3D (Pubitemid 36443190)
18. H Sun L Frassetto LZ Benet 2006 Effects of renal failure on drug transport and metabolism Pharmacol Ther 109 1 11 16085315 10.1016/j.pharmthera. 2005.05.010 1:CAS:528:DC%2BD2MXht12ktbbM (Pubitemid 41740811)
19. Pfister CU, Horak J, Horejsova M, Cieslarova B, Hasa J, Heine P, On N, Souppart C, Schaeffer N (2001) Pharmacokinetics of Femara in subjects with severe liver impairment. Proceedings of American Association for Cancer Research 42:544
20. JM Nabholtz 2008 Aromatase inhibitors in the management of early breast cancer Eur J Surg Oncol 34 1199 1207 18359182 1:STN:280:DC%2BD1cnos12itQ%3D%3D
21. CT Chung RW Carlson 2003 The role of aromatase inhibitors in early breast cancer Curr Treat Options Oncol 4 133 140 12594939 10.1007/s11864-003-0014-y
22. AC Wolff 2002 Systemic therapy Curr Opin Oncol 14 600 608 12409649 10.1097/00001622-200211000-00003 (Pubitemid 35387369)
23. JM Dixon CD Love CO Bellamy DA Cameron RC Leonard H Smith WR Miller 2001 Letrozole as primary medical therapy for locally advanced and large operable breast cancer Breast Cancer Res Treat 66 191 199 11510690 10.1023/A: 1010669403283 1:CAS:528:DC%2BD3MXmtFeqt7k%3D (Pubitemid 32675021)